impact of egfr mutation analysis in non-small cell lung cancer

 

 

 

 

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib therapy.18. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small-cell lung cancer. Keywords: Non-small-cell lung cancer Surgical resection Post-recurrence survival EGFR mutation EGFR-TKIs INTRODUCTION Treatment for recurrent disease is usually similar to that used for advanced disease however Objectives: To compare the rejection rates of non-small cell lung cancer ( NSCLC) samples obtained by differing sampling methods for testing by Sanger sequencing for epidermal growth factor receptor (EGFR) mutations. non-small cell lung cancer (NSCLC), has lower sensitivity compared with standard tissue genotyping but the presence of extrathoracic (M1b) disease may enhance the ability to identify EGFR mutations in plasma. 45. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non- small-cell lung cancer: analysis of aHan SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with getinib. OBJECTIVES: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase inhibitors (EGFR-TKIs) than those with wild type tumors. The strong association between smoking history and the presence of epidermal growth factor receptor (EGFR) mutations has been proven in nonsmall- cell lung cancer (NSCLC), which explains the favorable response to EGFRtyrosine kinase inhibitor ( EGFR-TKI) Quantitative and qualitative analyses of phase III first-line trials in EGFR mutation-positive NSCLC Epidermal growth factor receptor inhibition in mutation-positive non- small-cell lung cancer: is afatinib better or simply newer? Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta- analysis. In this report, we describe a novel oncogenic signaling pathway exclusively acting in mutated epidermal growth factor receptor (EGFR) non-small cell lung cancer ( NSCLC) with acquired tyrosine kinase inhibitor (TKI) resistance. Survival analysis of 178 non-small cell lung carcinoma patients with epithelial growth factor receptor mutations treated with first-generation tyrosinePark K, Tan EH, OByrne K, et al: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from theImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specim August 2014 Journal of Cancer Research and Clinical Oncology Impact FactorGefitinib monotherapy in previously treated advanced non-small cell lung cancer (NSCLC): An immunohi The overall EGFR mutation rate was 34.3 in patients with non-small cell lung cancer (NSCLC) and 43.3 in patients with adenocarcinoma. This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in theOptimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis. EGFR exon 20 insertion mutations in non-small cell lung cancer: preclinical data and clinical implications.Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta- analysis. J Natl Cancer Inst. Abstract. Epidermal growth factor receptor (EGFR) T790M mutation accounted for over half of drug resistance cases in EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) and led to different outcomes. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta- analysis. J Natl Cancer Inst.Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep. Relationship between EGFR and KRAS muta-tions and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-timePredictive and prognostic impact of epi-dermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. Liver metastasisNon-small cell lung cancer (NSCLC)Epidermal growth factor receptor (EGFR)EGFR tyrosin-kinase inhibitorsPrognosis.

Costa C, Molina MA, Drozdowskyj A, Gimnez-Capitn A, Bertran-Alamillo J, Karachaliou N et al (2014) The impact of EGFR T790M mutations and BACKGROUND: The strong association between smoking history and the presence of epidermal growth factor receptor (EGFR) mutations has been proven in non -small-cell lung cancer (NSCLC), which explains the favorable response to EGFR-tyrosine kinase inhibitor (EGFR-TKI) As in 1st line, do not use erlotinib without EGFR mutation analysis in 2nd line. First study to show continuation maintenance has an impact on the disease course of advanced NSCLC (including PFS and OS). A distinct subset of NSCLC A new therapeutic target in lung cancer. Although a few studies have described an association of family history of lung cancer with EGFR activating mutation, their impact on survival of lung cancer patients is unclear. Methods The study included consecutive 829 non- small-cell lung cancer patients who received analysis of EGFR Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Impact of EGFR mutation analysis in non-small cell lung cancer. (English). "Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis". Clinical Drug Investigation."The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies". Even though EGFR and KRAS mutations were thought to be mutually exclusive, some rare cases of concomitant EGFR and KRAS mutations haveThe Cancer and Leukemia Group B-9633 (CALGB-9633) phase III trial, including patients with stage IB non-small cell lung cancer randomized to The EGFR Mutation Analysis assay is an allele specific polymerase chain reaction (ASPCR) assay performed on the Rotor-Gene Q 5plex HRM(2009) Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer epidermal growth factor receptor (EGFR). non-small cell lung cancer ( NSCLC).Cheng, M.M. Palma, J.F. Scudder, S. Poulios, N. Liesenfeld, O. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non- Small Cell Lung Cancer. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 201014(12):5169.The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers. Documents. Keywords: KRAS, non-small cell lung cancer (NSCLC), adenocarcinoma, quantitative glycoproteomics, glycoprotein.Two distinct, non-overlapping mutations in adenocarcinomas include genomic alterations in the signaling proteins EGFR and KRAS that can result in constitutive activation X: multiple substitutions have been reported at an amino acid P: P-loop A: activation domain -C: -C helix domain EGFR: epidermal growth factor receptor NSCLC: non-small cell lung cancer TKI: tyrosine kinases inhibitor. Overview. Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in the progression to metastatic disease. The epidermal growth factor receptor (EGFR) and its ligands are frequently expressed in non-small-cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib have shown clinical activity in NSCLC. The development of central nervous system (CNS) metastases is a common and serious complication in nonsmall cell lung cancer (NSCLC), with an adverse impact on quality of life and survival (1) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta- analysis. EGFR mutations and clinical outcomes of chemotherapy for advanced non- small cell lung cancer: a meta-analysis.Impact of specific mu-tant KRAS on clinical outcome of EGFR-TKI-treated ad-vanced non-small cell lung cancer patients with an EGFR wild type genotype. Impact of eGFR inhibitor in NonSmall Cell Lung Cancer on Progression-Free and Overall Survival: A Meta- Analysis. J Natl Cancer Inst.BACKGROUND: Nonsmall-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine Implications of clonality in multifocal non small cell lung cancer.The Biomarkers V presentation highlight (O39.01) was a retrospective analysis of the CALGB 30406 study looking at the impact of specific EGFR mutations on outcomes. Non Small Cell Lung Cancer (NSCLC) is the major subtype of lung cancers (85) which is the leading cause of cancer related deaths worldwide.In NSCLC, EGFR can be altered either by over-expression or by different mutations. Abstract. Targeting epidermal growth factor receptor (EGFR) in patients with non-small-cell lung cancer (NSCLC) having EGFR mutations is associated with an improved overall survival. Molecular analysis of the mutation status for EGFR and KRAS are now routine in the management of non-small cell lung cancer.

Radiogenomics, the linking of medical images with the genomic properties of human tumors, provides exciting opportunities for non-invasive diagnostics and prognostics. The study included consecutive 829 non-small-cell lung cancer patients who received analysis of EGFR mutation in a prospective lung cancer cohort.The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer. Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.Impact of specific mutant K-ras on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Background: Mutational analysis of the Epidermal Growth Factor Receptor ( EGFR) and K-ras genes to select non-small cell lung cancer (NSCLC) patients for treatment with novel EGFR tyrosine kinase inhibitors is an appealing possibility currently under investigation. EGFR Mutation, Chemotherapy, Non-Small Cell Lung Cancer, Me-ta-Analysis.Due to insufficient data, we could not conduct a subgroup analysis for EGFR exon 18 and exon 20 mutations to determine the impact of chemotherapy on general EGFR loci however, EGFR exon 19 deletions and Epidermal growth factor receptor (EGFR) mutation. EGFR is part of the ErbB family of cell surface receptor tyrosine kinases, which control signal trans-duction pathways thatTargeted therapies in non-small cell lung cancer: which implication in routine practice. We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status.

related notes